Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Korea United PharmXKRX:033270 -1.38%90 Days Payable is 30.54 as of Jun. 2026, which is 18% above its 10-year median of 25.85. GuruFocus rates XKRX:033270 with a GF Score™ of 90/100 and a GF Value™ of ₩20,354.74 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Korea United Pharm ranks worse than 92.52% on this metric.
The historical rank and industry rank for Korea United Pharm's Days Payable or its related term are showing as below:
XKRX:033270'
s Days Payable Range Over the Past 10 Years
Min: 21.35 Med: 25.85 Max: 29.54
Current: 27.45
During the past 13 years, Korea United Pharm's highest Days Payable was 29.54. The lowest was 21.35. And the median was 25.85.
XKRX:033270's Days Payable is ranked worse than 92.52% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.47
vs XKRX:033270: 27.45
Korea United Pharm's Days Payable
increased
from Jun. 2025 (26.20) to Jun. 2026 (30.54).
It may suggest that Korea United Pharmdelayed paying its suppliers.
The historical data trend for Korea United Pharm's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Korea United Pharm's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Korea United Pharm Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Korea United Pharm's Days Payable distribution charts can be found below:
* The bar in red indicates where Korea United Pharm's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Korea United Pharm's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Korea United Pharm (XKRX:033270) has a Days Payable of 30.54 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Korea United Pharm and its competitors. This is 18% above median its historical median of 25.85. Over the past decade, Korea United Pharm's Days Payable has ranged from 21.35 to 29.54. According to the industry distribution chart, Korea United Pharm ranks #854 out of 923 companies in the Drug Manufacturers industry, placing it in the top 92.5%.
Is Korea United Pharm's Days Payable too high?
Korea United Pharm's current Days Payable of 30.54 is 18% above median its 10-year median of 25.85. Over the past 10 years, this metric has ranged from a low of 21.35 to a high of 29.54. The Drug Manufacturers industry median Days Payable is 88.47. Korea United Pharm's value of 30.54 is 65.5% below this industry median. Based on the distribution chart, Korea United Pharm ranks #854 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Korea United Pharm has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Korea United Pharm's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Korea United Pharm ranks #854 out of 923 companies for Days Payable. This places Korea United Pharm in the lower half of its industry. The industry median Days Payable is 88.47. Korea United Pharm's value of 30.54 is 65.5% below this benchmark. Historically, Korea United Pharm's own Days Payable has ranged from 21.35 to 29.54 over the past decade. While the company's 10-year median is 25.85 vs. the industry median of 88.47, Korea United Pharm has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.47, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Korea United Pharm's current Days Payable of 30.54 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Korea United Pharm and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Korea United Pharm's current Days Payable is 30.54, which is 18% above median its own 10-year median of 25.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Korea United Pharm stock overvalued right now?
Based on GuruFocus' analysis, Korea United Pharm (XKRX:033270) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩20,354.74, compared to a current price of ₩17,910.00 — trading 12% below its estimated fair value. The current Days Payable is 30.54, which is 18% above median its 10-year median of 25.85 and 65.5% below the Drug Manufacturers industry median of 88.47. Korea United Pharm's overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Korea United Pharm (XKRX:033270), the current Days Payable is 30.54 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Korea United Pharm (XKRX:033270) Overvalued in 2026?
Based on GuruFocus' analysis, Korea United Pharm stock appears to be undervalued.
The current stock price of ₩17,910.00 is trading 12% below its estimated GF Value™ of ₩20,354.74.
GuruFocus considers Korea United Pharm to be Modestly Undervalued.
Key valuation signals for XKRX:033270:
Days Payable: 30.54 (18% above median its 10-year median of 25.85)
GF Value™: ₩20,354.74 vs. price of ₩17,910.00 (12% below fair value)
Industry Position: 65.5% below the Drug Manufacturers median (#854 of 923)
No single metric tells the full story. See the XKRX:033270 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Korea United Pharm Inc is a South Korea based company engages in the manufacture and distribution of pharmaceuticals and healthcare products. It offers incrementally modified drug, anti-cancer, prescription, and OTC products.
90GF Score
Get the complete analysis for XKRX:033270
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:033270 has been successfully added to your 
